Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts

Bridons research contributions include: Development of Drug Affinity Complex (DAC) technology for albumin binding and peptide half-life extension Identification and characterization of CJC-1295 as a long-lasting GRF analog with sustained growth hormone-releasing properties Pioneering work on maleimido-derivatized GHRH analogs and their bioconjugation to serum albumin Demonstration of 4-fold increase in growth hormone area-under-curve with optimized CJC-1295 formulation versus native GHRH Extensive in vitro and in vivo pharmacological characterization in rat and human models His 2005 publication in Endocrinology titled Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog remains the foundational reference for CJC-1295 research, establishing the peptides mechanism of action and pharmacokinetic profile that enabled subsequent clinical investigation

Chen W, Wu P, Yu F, Luo G, Qing L, Tang J
Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg) $87.00 Fragment 176-191 & CJC-1295 & Ipamorelin Blend are Synthesized and Lyophilized in the USA
L-Carnitine: Transports fatty acids into mitochondria for energy production, aiding in fat metabolism and endurance
HydraFacial vs traditional facial offers complementary skin protection education